课题基金 / 基金详情

Molecular Genetics of Hereditary Endoplasmic Reticulum Diabetes

Molecular Genetics of Hereditary Endoplasmic Reticulum Diabetes
遗传性内质网糖尿病的分子遗传学
批准号:
10615191
负责人:
Bohdan Khomtchouk
金额:
$54.81万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-05-01 至 2026-04-30

项目摘要

项目成果

Bohdan Khomtchouk的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Abstract The endoplasmic reticulum (ER) is best known for its role as the locus of protein folding, calcium storage, and lipid metabolism. The organelle also integrates numerous other molecular pathways and contributes to cellular calcium homeostasis, reduction-oxidation regulation, and cell death. Given the many vital and complex functions of the ER, it is little wonder that its failure can trigger a range of diseases. It has been shown that dysregulation of ER homeostasis may underlie β cell dysfunction and death in type 1 and type 2 diabetes, as well as in monogenic forms of diabetes, including Wolfram syndrome, Wolcott-Rallison syndrome, microcephaly, epilepsy, and diabetes syndrome (MEDS), and mutant insulin gene-induced diabetes caused by pathogenic variants in the WFS1 and CISD2, EIF2AK3, IER3IP1, and INS genes respectively. To further understand the contribution of ER dysfunction to β cell death and design novel treatments targeting ER for diabetes, we need to establish functional studies of gene variants affecting ER homeostasis, design treatments targeting common molecular pathways altered in ER stressed β cells, and identify other ER genes involved in β cell dysfunction and death. In this proposal, we will characterize WFS1 and CISD2, EIF2AK3, IER3IP1, and INS variants using functional assays and bioinformatics and test novel treatments targeting the common molecular pathways altered in β cells expressing pathogenic variants of WFS1 and CISD2, EIF2AK3, IER3IP1, and INS genes. Successful completion of this study will lead to the establishment of precision medicine for hereditary ER diabetes.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
CETP and SGLT2 inhibitor combination therapy improves glycemic control.
CETP 和 SGLT2 抑制剂联合治疗可改善血糖控制。
DOI: 10.1101/2023.06.13.23291357
发表时间: 2023
期刊: medRxiv : the preprint server for health sciences
影响因子: --
作者: [Khomtchouk,BohdanB, Sun,Patrick, Ditmarsch,Marc, Kastelein,JohnJP, Davidson,MichaelH]
通讯作者: Davidson,MichaelH
DOI: 10.1016/j.ymthe.2023.04.020
发表时间: 2023-06-07
期刊: MOLECULAR THERAPY
影响因子: 12.4
作者: [Winter, Hanna, Winski, Greg, Busch, Albert, Chernogubova, Ekaterina, Fasolo, Francesca, Wu, Zhiyuan, Baecklund, Alexandra, Khomtchouk, Bohdan B., Booven, Derek J. Van, Sachs, Nadja, Eckstein, Hans-Henning, Wittig, Ilka, Boon, Reinier A., Jin, Hong, Maegdefessel, Lars]
通讯作者: Maegdefessel, Lars
DOI: 10.1038/s41598-023-28965-7
发表时间: 2023-02-06
期刊: Scientific reports
影响因子: 4.6
作者: []
通讯作者:
Molecular Genetics of Hereditary Endoplasmic Reticulum Diabetes
  • 批准号:
    10417734
  • 项目类别:
  • 资助金额:
    $56.95万
  • 财政年份:
    2022
  • 负责人:
    Bohdan Khomtchouk
  • 依托单位:
海外基金